VIDAVO SA

Vidavo SA manufactures the VIDA24, a continuous glucose monitoring (CGM) system. This device is designed to provide real-time blood glucose measurements for diabetic patients by using a subcutaneous sensor. The data is wirelessly transmitted to companion mobile or desktop applications, enabling users to monitor and manage their glucose levels continuously.

Vidavo SA is based in Greece. The company operates from this location while developing and manufacturing its authorised medical devices, including the VIDA24, in compliance with relevant regulatory standards.

Vidavo SA’s devices, such as the VIDA24, are listed in the EUDAMED database. This registry is the official European Union database for medical devices, ensuring transparency and traceability of authorised products under the EU Medical Device Regulation (MDR).

The VIDA24, Vidavo SA’s continuous glucose monitoring system, is classified as a Class IIa medical device under the EU Medical Device Regulation (MDR). This classification is determined based on factors like the device’s intended purpose, risk profile, and potential impact on patient safety, with Class IIa representing a moderate risk requiring additional scrutiny and compliance measures.